Latest by Sony Salzman
The FDA approved the fixed-dose combination of emtricitabine and tenofovir alafenamide for PrEP, but advocates hope to see more research on the HIV prevention drug's efficacy for receptive vaginal sex for cisgender women and transgender men.
At IDWeek in Washington, D.C., leading infectious disease doctors and researchers met with U.S. Congress leadership to discuss HIV prevention, treatment, and care policy.
We're covering the latest news and research from this major interdisciplinary meeting on infectious diseases, which takes place in Washington, D.C., from Oct. 2 to Oct. 6.
But other research links prisons themselves to mental health challenges and infectious disease outbreaks.
"Genetics is less than half the story for sexual behavior, but it's still a contributing factor."
A chlamydia infection makes HIV acquisition more likely.
The results were less favorable than expected, but experts -- and women who participated in the trial -- would like to see this prevention tool approved for use.
The ECHO trial faces backlash and criticism.
Researchers reported hopeful news on regimens with lower treatment burdens and newly developed antiretrovirals.
Although several HCV drugs can cure almost all infections regardless of viral genotype, picking the right drug will depend on each patient's medical history, level of liver damage, and coinfections.